Immunomodulatory Receptor ILT3/LILRB4 Protects Human Leukemic B Cells From Ferroptosis In Vitro
European Journal of Immunology · 2026-10 · 56 (10)
DOI: 10.1002/eji.70289 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, online erschienen am 08.10.2026. Verfasst von Roberta Drago und 11 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione Toscana Life Sciences, Siena, Italy. Hauptthemen laut MEDLINE: Receptors, Immunologic, Leukemia, Lymphocytic, Chronic, B-Cell, Ferroptosis, Membrane Glycoproteins. Die Arbeit nennt 78 Literaturangaben. Gefördert von: Fondazione AIRC per la ricerca sul cancro ETS, Ministero dell'Istruzione, dell'Università e della Ricerca, Ministero dell’Istruzione, dell’Università e della Ricerca.
Abstract (Originalsprache)
Immunoregulatory receptors determine immune cell fate by cell‐intrinsic and cell‐extrinsic mechanisms. In cancer, such feedback may enhance the selective advantage and immune evasion of tumor cells. Immunoglobulin‐like transcript 3 (ILT3 or LILRB4) is an immunomodulatory receptor ectopically expressed on the surface of chronic lymphocytic leukemia (CLL) cells, but its role in CLL remains poorly understood. Here, we identified ILT3 as a marker of proliferating CLL cells co‐expressed with immunoregulatory genes including IL‐10 , TNFRSF4 , CD276 , and IRS2 . Notably, ILT3 expression is enriched in the proliferative CXCR4 low CD5 high subset of circulating CLL cells and in tumor cells residing in the lymph node proliferative niche, linking ILT3 expression to tumor proliferative states. CRISPR/Cas9‐mediated ILT3 loss reduced survival of proliferating CLL cells and induced transcriptomic signatures of metabolic distress in an in vitro model recapitulating lymph node‐driven proliferation. Mechanistic studies revealed that ILT3 limits lipid peroxidation and protects CLL cells from ferroptosis, a form of lipid peroxidation‐driven cell death that has emerged as a cancer vulnerability. Overall, our findings identify ILT3 as a key marker of the immunoregulatory program in proliferating CLL cells and illustrate that immunomodulatory receptors contribute to the maintenance of tumor metabolic homeostasis during human CLL cell proliferation in vitro.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fondazione Toscana Life Sciences, Siena, Italy.
- PhD Program in Translational and Precision Medicine, University of Siena, Siena, Italy.
- Università degli Studi di Palermo, Palermo, Italy.
- Department of Mathematics, Informatics and Geosciences, University of Trieste, Trieste, Italy.
- University Hospital of Bonn, Medical Clinic and Polyclinic III Internal Medicine for Oncology, Hematology, and Rheumatology, Bonn, Germany.
- Division of Immune Diversity, German Cancer Research Center (DKFZ), Heidelberg, Germany.
ORCID-Profile: Roberta Drago, Rosita Del Prete, Virginia Anna Gazziero, Giulio Caravagna, Danilo Licastro, Monica Bocchia, Alessandro Gozzetti, Anna Kabanova, Federica Nardi
Förderung
- Fondazione AIRC per la ricerca sul cancro ETS
- Ministero dell'Istruzione, dell'Università e della Ricerca
- Ministero dell’Istruzione, dell’Università e della Ricerca
Zitieren
APA
Drago, R., Prete, R. D., Bartolini, G., Gazziero, V. A., Kabdolova, A., Pezzella, L., Caravagna, G., Licastro, D., Bocchia, M., Gozzetti, A., Kabanova, A., & Nardi, F. (2026). Immunomodulatory Receptor ILT3/LILRB4 Protects Human Leukemic B Cells From Ferroptosis In Vitro. European Journal of Immunology, 56(10). https://doi.org/10.1002/eji.70289
Vancouver
Drago R, Prete RD, Bartolini G, Gazziero VA, Kabdolova A, Pezzella L, et al. Immunomodulatory Receptor ILT3/LILRB4 Protects Human Leukemic B Cells From Ferroptosis In Vitro. European Journal of Immunology. 2026;56(10). doi:10.1002/eji.70289
BibTeX
@article{Drago2026,
author = {Drago, Roberta and Prete, Rosita Del and Bartolini, Gaia and Gazziero, Virginia Anna and Kabdolova, Alua and Pezzella, Laura and Caravagna, Giulio and Licastro, Danilo and Bocchia, Monica and Gozzetti, Alessandro and Kabanova, Anna and Nardi, Federica},
title = {Immunomodulatory Receptor ILT3/LILRB4 Protects Human Leukemic B Cells From Ferroptosis In Vitro},
journal = {European Journal of Immunology},
year = {2026},
volume = {56},
number = {10},
doi = {10.1002/eji.70289}
}
EUVIMED